-
Recent Posts
Archives
- June 2019
- May 2018
- January 2018
- September 2017
- July 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- September 2013
- August 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
Categories
-
Join 204 other subscribers
Monthly Archives: September 2013
Making CNS Pay Off
In preparing the October issue of NeuroPerspective, we noted that September was another solid month for the neuroscience stock sector, with a number of companies showing dramatic valuation gains. In fact, the index was up over 11% in just the … Continue reading
Fear and Loathing in Las Vegas*: The Persistence of Gonzo Neuroscience
Like a chronic gambler who keeps thinking that the next time will turn out different, the pharma industry has developed a nasty habit of sidling back to the Alzheimer’s roulette table, putting all their chips on 7, and watching forlornly … Continue reading